Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT04203797
- Locations
- 🇵🇱
Regeneron Study Site, Lubin, Dolnoslaskie, Poland
🇩🇪IKF Pneumologie GmbH & Co. KG - Institut fuer klinische Forschung Pneumologie Frankfurt (Clinical Research Centre Respiratory Medicine) to IKF Pneumologie Frankfurt GmbH & Co KG., Frankfurt am Main, Hessen, Germany
🇩🇪IKF Pneumologie Mainz, Helix Medical Excellence Center Mainz, Mainz, Rheinland-Pfalz, Germany
Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT04173442
- Locations
- 🇺🇸
Regeneron Research Site, La Jolla, California, United States
REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT04162470
- Locations
- 🇬🇧
Regeneron Study Site, Leeds, United Kingdom
Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy
- Conditions
- Generalized Lipodystrophy
- Interventions
- Drug: PlaceboDrug: Low-Dose REGN4461Drug: High-dose REGN4461
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 16
- Registration Number
- NCT04159415
- Locations
- 🇹🇷
Regeneron Research Site, Izmir, Turkey
Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
- Conditions
- Cutaneous Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2019-11-07
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 79
- Registration Number
- NCT04154943
- Locations
- 🇩🇪
Regeneron Study Site, Tübingen, Germany
Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
- Conditions
- Neovascular (Wet) Age-Related Macular Degeneration
- Interventions
- Drug: High-dose aflibercept
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 106
- Registration Number
- NCT04126317
- Locations
- 🇵🇷
Regeneron Study Site, Arecibo, Puerto Rico
Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity
- Conditions
- Retinopathy of Prematurity
- Interventions
- Procedure: laser photocoagulation
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 127
- Registration Number
- NCT04101721
- Locations
- 🇻🇳
Regeneron Study Site, Hue, Vietnam
First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)
- Conditions
- Relapsed Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT04083534
- Locations
- 🇺🇸
Regeneron Study Site, Milwaukee, Wisconsin, United States
REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 82
- Registration Number
- NCT04077099
- Locations
- 🇰🇷
Regeneron Research Facility, Seoul, Korea, Republic of
🇫🇷Regeneron Study Site, Caen cedex, France
A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC)Clear Cell Renal Cell Carcinoma (ccRCC)
- Interventions
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 345
- Registration Number
- NCT03972657
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
🇺🇸John Wayne Cancer Institute (JWCI), Santa Monica, California, United States
🇺🇸Sarah Cannon Research Institute (SCRI), Denver, Colorado, United States